AstraZeneca to Supply Additional Doses of AZD7442 to the U.S. for COVID-19
AstraZeneca (AZN) has modified an existing agreement with the U.S. Government to supply up to 500,000 additional doses of AZD7442 - a long-acting antibody (LAAB) combination in late-stage development, for the prevention and treatment of COVID-19.
We stress . . .
This content is for paid subscribers.
Today’s Highlights
March 17, 2021
